Arca Biopharma Inc
General ticker "ABIO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $46.2M
Arca Biopharma Inc follows the US Stock Market performance with the rate: 41.2%.
Estimated limits based on current volatility of 10.7%: low 24.66$, high 30.58$
Factors to consider:
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [16.55$, 39.56$]
- 2024-12-30 to 2025-12-30 estimated range: [23.27$, 50.99$]
Financial Metrics affecting the ABIO estimates:
- Negative: Non-GAAP EPS of -0.37 <= 0.08
- Negative: Operating Income to Revenue ratio of -1.00 <= 0.01
- Negative: negative Net Income
- Negative: Operating Cash Flow per share of -0.35 <= 0.20
- Negative: Industry Operating Cash Flow per share (median) of -1.55 <= 0.28
- Positive: Interest Expense per share of 0 <= 0
Short-term ABIO quotes
Long-term ABIO plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $19.34MM | $10.60MM | $7.30MM |
| Operating Income | $-19.34MM | $-10.60MM | $-7.30MM |
| Non-Operating Income | $0.01MM | $0.68MM | $1.96MM |
| Interest Expense | $0.00MM | $0.68MM | $0.00MM |
| R&D Expense | $13.83MM | $4.75MM | $1.01MM |
| Income(Loss) | $-19.32MM | $-9.92MM | $-5.34MM |
| Profit(Loss) | $-19.32MM | $-9.92MM | $-5.34MM |
| Stockholders Equity | $51.04MM | $41.67MM | $37.02MM |
| Assets | $54.92MM | $43.09MM | $37.86MM |
| Operating Cash Flow | $-18.76MM | $-10.91MM | $-5.01MM |
| Investing Cash Flow | $-0.04MM | $-0.00MM | $0.00MM |
| Financing Cash Flow | $23.09MM | $0.00MM | $0.00MM |
| Earnings Per Share* | $-1.38 | $-0.64 | $-0.37 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.